Table 2

Clinical Outcomes of Trials With Newer-Generation DES

Trial (Ref. #)nIndicationClopidogrel Therapy (Months)Follow-Up TimeDES TypeCardiac Death (%)MI (%)TLR (%)MACE (%)Definition of MACEPer Protocol Stent Thrombosis
SPIRIT II (15)300Selected patients63 yrsEES vs. PES
  • 0.5 vs. 4.3

  • p = NS

  • 3.6 vs. 7.2

  • p = NS

  • 4.6 vs. 10.1

  • p = NS

  • 7.2 vs. 15.9

  • p < 0.05

Cardiac death, MI, TLR
  • 2.1 vs. 4.4

  • p = NS

SPIRIT III (16)1,002Selected patients63 yrsEES vs. PES
  • 1.6 vs. 2.0

  • p = NS

  • 3.8 vs. 6.6

  • p = 0.07

  • 5.7 vs. 9.2

  • p = NS

  • 9.7 vs. 16.4

  • p = 0.004

Cardiac death, MI, TLR
  • 1.0 vs. 1.7

  • p = NS

SPIRIT IV (17)3,690Selected patients1212 monthsEES vs. PES
  • 0.4 vs. 0.4

  • p = NS

  • 1.9 vs. 3.1

  • p = 0.02

  • 2.5 vs. 4.6

  • p = 0.001

  • 4.2 vs. 6.9

  • p = 0009

Cardiac death, MI, TLR
  • 0.2 vs. 0.9

  • p = 0.004

ENDEAVOR II (18)1,197Selected patients35 yrsZES vs. BMS
  • 3.1 vs. 3.6

  • p = NS

  • 3.8 vs. 4.8

  • p = NS

  • 7.5 vs. 16.3

  • p < 0.001

  • 15.4 vs. 24.6

  • p < 0.001

Death, MI, TLR
  • 0.5 vs. 1.4

  • p = NS

ENDEAVOR III (19)436Selected patients34 yrsZES vs. SES
  • 0.3 vs. 1.8

  • p = NS

  • 1.0 vs. 4.5

  • p < 0.05

  • 7.8 vs. 6.4

  • p = NS

  • 12.7 vs. 19.1

  • p = NS

  • Death, MI, TLR

  • 0.0 vs. 0.0

  • p = NS

ENDEAVOR IV (20)1,548Selected patients63 yrsZES vs. SES
  • 1.6 vs. 2.3

  • p = NS

  • 2.2 vs. 4.9

  • p = 0.007

  • 6.5 vs. 6.0

  • p = NS

  • 11.4 vs. 13.8

  • p = NS

Death, MI, TLR
  • 1.0 vs. 1.0

  • p = NS

EES = everolimus-eluting stent(s); MACE = major adverse cardiovascular events; ZES = zotarolimus-eluting stent(s); other abbreviations in Table 1.